$2.51+0.05 (+2.03%)
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products.
PMGC Holdings Inc. in the Healthcare sector is trading at $2.51. The stock is currently near its 52-week low of $1.62, remaining 97.0% below its 200-day moving average. Technical signals show oversold RSI of 5 and bullish MACD crossover, explaining why ELAB maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to add...
US stocks looked set to open higher in Wednesday's trading session after President Trump claimed tha
Nu Holdings Ltd. 57,555,137 13.98
Recent developments in the AI chip industry have underscored the strategic importance of precision manufacturing in supporting critical supply chains. PMGC Holdings Inc. recently completed the acquisition of AGA Precision Systems LLC, a California-based CNC machining company. This acquisition is part of a broader trend towards reshoring and strengthening domestic manufacturing capabilities, particularly for industries like aerospace and defense. As demand for high-tolerance and specialty...
Northstrive Biosciences announced the initiation of Phase II of the AI Development Program with strategic partner Yuva Biosciences. As part of the Phase II objective, both companies will collaborate to leverage MitoNova, YuvaBio’s AI mitochondrial science-focused artificial intelligence platform, to compile a selection of small molecule candidates that promote mitochondrial health in obesity and cardiac diseases. YuvaBio will use MitoNova to virtually screen a large-scale library of diverse, dru